Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
April 17, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
March 30, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
- Full enrollment of the LUNA trial anticipated in the second half of 2023 - - LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 - - LUNA...
Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 27, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025...
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
November 04, 2022 12:08 ET
|
Adverum Biotechnologies, Inc.
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in...
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
October 27, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
September 30, 2022 16:45 ET
|
Adverum Biotechnologies, Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
September 27, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...